Akebia Therapeutics (AKBA) Gains from Sales and Divestitures (2016 - 2019)

Akebia Therapeutics (AKBA) has 4 years of Gains from Sales and Divestitures data on file, last reported at $323136.0 in Q4 2019.

• Gains from Sales and Divestitures for Q4 2019 came in at $323136.0, down 60.52% year-over-year; the trailing twelve-month figure through Dec 2019 was $323136.0 (down 60.52% YoY), and the FY2019 annual result was $323136.0, down 60.52% from the prior year.
• Gains from Sales and Divestitures slipped to $323136.0 in Q4 2019 per AKBA's latest filing, from $818395.0 in the prior quarter.
• Over five years, Gains from Sales and Divestitures peaked at $818395.0 in Q4 2018 and troughed at $90566.0 in Q4 2017.
• A 4-year average of $335196.2 and a median of $215912.0 in 2016 frame the typical range for Gains from Sales and Divestitures.
• The sharpest annual moves came in 2018 and 2019: Gains from Sales and Divestitures surged 803.64% in 2018, then tumbled 60.52% in 2019.
• A 4-year view of Gains from Sales and Divestitures shows it stood at $108688.0 in 2016, then dropped by 16.67% to $90566.0 in 2017, then surged by 803.64% to $818395.0 in 2018, then plunged by 60.52% to $323136.0 in 2019.
• Business Quant data shows AKBA's Gains from Sales and Divestitures at $323136.0 in Q4 2019, $818395.0 in Q4 2018, and $90566.0 in Q4 2017.